Email Us
The Trial Lawyer Magazine Logo
SUBSCRIBE

FDA Asks Leukemia Drug Maker to Suspend Marketing, Sales over Blood Clot Dangers
FDA Asks Leukemia Drug Maker to Suspend Marketing, Sales over Blood Clot Dangers

News Inferno; November 1, 2013

The U.S. Food and Drug Administration (FDA) just issued an updated Drug Safety Communication asking Ariad Pharmaceuticals, the maker of the leukemia drug, Iclusig (ponatinib), to suspend its marketing and sales following increased reports of serious blood clots in arteries and veins. Iclusig received FDA approval in December 2012.

The October 31, 2013 Communication is a follow-up to its prior announcement dated October 11, 2013.

The agency indicated that it would continue to evaluate Iclusig to better understand its risks-benefit profile, and advises patients currently being treated with Iclusig to speak to their heath care professionals concerning continuing treatment. Ariad Pharmaceuticals indicated that it agreed with the agency’s request.

To read the complete article, please click here: https://www.newsinferno.com/fda-asks-leukemia-drug-maker-to-suspend-marketing-sales-over-blood-clot-dangers/

Generic selectors
Exact matches only
Search in title
Search in content
The Trial Lawyer Magazine Logo
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram